A Therepeutic Trial with Low-dose Ara-C in Acute Nonlymphocytic Leukemia and Myelodysplastic Syndromes: a Study of 15 cases

DOI Web Site PubMed 1 Citations
  • MARUTA Atsuo
    Department of Hematology and Chemotherapy, Kanagawa Cancer Center
  • MIYASHITA Hiroko
    Department of Hematology and Chemotherapy, Kanagawa Cancer Center
  • KODAMA Fumio
    Department of Hematology and Chemotherapy, Kanagawa Cancer Center
  • HARANO Hiroshi
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • KANAMORI Heiwa
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • TAKAHASHI Kenichi
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • NOGUCHI Tahei
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • MATSUZAKI Michio
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • OGAWA Koji
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • MOTOMURA Shigeki
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • SAKURAI Masako
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • ITO Akira
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • OOKUBO Takao
    First Department of Internal Medicine, Yokohama City University School of Medicine
  • WATANABE Shinichiro
    Central Laboratory for Clinical Investigation, Yokohama City University Hospital
  • MOHRI Hiroshi
    Central Laboratory for Clinical Investigation, Yokohama City University Hospital

Bibliographic Information

Other Title
  • 急性非リンパ性白血病および類縁疾患におけるAra-C少量療法15例の臨床的検討
  • キュウセイ ヒ リンパセイ ハッケツビョウ オヨビ ルイエン シッカン ニ

Search this article

Abstract

Eleven patients with ANLL, two with RAEB and two with hypoplastic leukemia were treated with a low-dose of Ara-C (LDAC) at a dose of 5.9-10.0 mg/m2, s.c. every 12h or 6h. for 14-47 days. Complete remission was obtained in eight patients (53%). CR was obtained in three of five patients with ANLL who had shown no response to the conventional combined chemotherapy of BH-AC DMP or BH-AC AMP. Two patients with overt ANLL occuring from MDS did not respond to LDAC. In the patients with RAEB, CR was obtained in one and only PR in another. CR was also obtained in both patients with hypoplastic leukemia. Severe myelosuppression was observed in all but one patient when one course of LDAC was administered to the patients as a consolidation therapy after CR was once obtained. Relapse was occured in all of the patients. The remission duration was 17-38 weeks (median 25 weeks). However, CR was successfully reinduced with the same LDAC in three of the six patients with relapse. One of them has been tried to submit to a monthly therapy of 10 days of LDAC as a maintenance therapy and has been still in remission for more than 52 weeks after reinduced to CR. These observations suggest that long CR duration cannot be obtained with the LDAC induction therapy alone, though LDAC is of value in the treatment of ANLL.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 29 (1), 8-13, 1988

    The Japanese Society of Hematology

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top